While most Japanese biotechs struggle to get deals done with international partners, Chiome Bioscience Inc.'s strategy to use experienced consultants and adapt its technology to incorporate its partners' feedback has allowed the antibody discovery company to do three deals with U.S. and European companies in the last six months.

Since January 2011, there have been about 19 deals between Japanese biotechs and U.S. or European companies that go beyond Japan-only rights. All but one company - Chiome - did only a single deal.